Pluri, Inc. ("Pluri", the "Company", "we" or "us") (Nasdaq, TASE: PLUR), a biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced the completion of the first phase of its program with Resbiomed Technologies OOD ("Resbiomed"), a European biotechnology company developing extracellular-matrix-based biomaterials and biologics for regenerative medicine. The program is being executed through Pluri's contract development and manufacturing division, PluriCDMO™.
In June 2025, Pluri Biotech Ltd., a wholly owned subsidiary of the Company, and a provider of Contract Development and Manufacturing ("CDMO") services under its PluriCDMO™ business line, entered into an agreement with Resbiomed to apply Pluri's proprietary placenta-derived processing and bioprocessing capabilities to enhance, standardize and enable scalable production of placenta-derived biomaterials containing naturally occurring human collagen. The parties have completed the planned first phase of work, focusing on initial process development and feasibility, and are moving forward to the next phase, which is focused on further advancing process definition, reproducibility and manufacturing readiness, subject to mutually agreed scope, timelines and applicable requirements.